BC Innovations | Mar 21, 2013
Cover Story

Applying high throughput to CLL

Boston researchers have provided a detailed look at how cancer genome evolution alters clinical outcomes in chronic lymphocytic leukemia, 1 and a Michigan team has identified a new transcriptional fusion that could broadly contribute to...
BC Innovations | Feb 28, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Chronic lymphocytic leukemia (CLL) Yippee-like 5 (YPEL5); protein phosphatase 1 catalytic subunit b-isozyme (PPP1CB) Patient sample and cell culture studies have identified a YPEL5-PPP1CB fusion...
Items per page:
1 - 2 of 2